Literature DB >> 7551219

Adjuvant properties of aluminum and calcium compounds.

R K Gupta1, B E Rost, E Relyveld, G R Siber.   

Abstract

It is likely that aluminum compounds will continue to be used with human vaccines for many years as a result of their excellent track record of safety and adjuvanticity with a variety of antigens. For infections that can be prevented by induction of serum antibodies, aluminum adjuvants formulated under optimal conditions are the adjuvants of choice. It is important to select carefully the type of aluminum adjuvant and optimize the conditions of adsorption for every antigen since the degree of adsorption of antigens onto aluminum adjuvants markedly affects immunogenicity. The mechanism of adjuvanticity of aluminum compounds includes formation of a depot at the site of injection from which antigen is released slowly; stimulation of immune-competent cells of the body through activation of complement, induction of eosinophilia, and activation of macrophages; and efficient uptake of aluminum-adsorbed antigen particles by antigen-presenting cells because of their particulate nature and optimal size (< 10 microns). Limitations of aluminum adjuvants include local reactions, production of IgE antibodies, ineffectiveness for some antigens, and inability to elicit cell-mediated immune responses especially cytotoxic T-cell responses. Calcium phosphate, which has adjuvant properties similar to aluminum adjuvants, has the potential advantages of being a natural component of the body and of not increasing IgE production. There is a need for alternative adjuvants, particularly for diseases in which cell-mediated immune responses are important for prevention or cure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7551219     DOI: 10.1007/978-1-4615-1823-5_8

Source DB:  PubMed          Journal:  Pharm Biotechnol        ISSN: 1078-0467


  40 in total

1.  Near-Infrared 1064 nm Laser Modulates Migratory Dendritic Cells To Augment the Immune Response to Intradermal Influenza Vaccine.

Authors:  Kaitlyn Morse; Yoshifumi Kimizuka; Megan P K Chan; Mai Shibata; Yusuke Shimaoka; Shu Takeuchi; Benjamin Forbes; Christopher Nirschl; Binghao Li; Yang Zeng; Roderick T Bronson; Wataru Katagiri; Ayako Shigeta; Ruxandra F Sîrbulescu; Huabiao Chen; Rhea Y Y Tan; Kosuke Tsukada; Timothy Brauns; Jeffrey Gelfand; Ann Sluder; Joseph J Locascio; Mark C Poznansky; Niroshana Anandasabapathy; Satoshi Kashiwagi
Journal:  J Immunol       Date:  2017-07-14       Impact factor: 5.422

2.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

Review 3.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

Review 4.  Laser vaccine adjuvants. History, progress, and potential.

Authors:  Satoshi Kashiwagi; Timothy Brauns; Jeffrey Gelfand; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Authors:  Puneet K Gupta; Paushali Mukherjee; Shikha Dhawan; Alok K Pandey; Suman Mazumdar; Deepak Gaur; S K Jain; Virander S Chauhan
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

6.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

7.  Brief Exposure of Skin to Near-Infrared Laser Modulates Mast Cell Function and Augments the Immune Response.

Authors:  Yoshifumi Kimizuka; Wataru Katagiri; Joseph J Locascio; Ayako Shigeta; Yuri Sasaki; Mai Shibata; Kaitlyn Morse; Ruxandra F Sîrbulescu; Mizuki Miyatake; Patrick Reeves; Makoto Suematsu; Jeffrey Gelfand; Timothy Brauns; Mark C Poznansky; Kosuke Tsukada; Satoshi Kashiwagi
Journal:  J Immunol       Date:  2018-11-12       Impact factor: 5.422

8.  Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.

Authors:  L Holten-Andersen; T M Doherty; K S Korsholm; P Andersen
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.

Authors:  Tia Estey; Christina Vessely; Theodore W Randolph; Ian Henderson; Latoya Jones Braun; Rajiv Nayar; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

10.  Disparate adjuvant properties among three formulations of "alum".

Authors:  Derek W Cain; Sergio E Sanders; Michael M Cunningham; Garnett Kelsoe
Journal:  Vaccine       Date:  2012-11-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.